Arontier Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Out of Business

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Out of Business

Arontier General Information

Description

Developer of artificial intelligence-driven drug discovery platform intended for incurable and rare diseases. The company's platform offers tools for drug discovery, the development of anti-CAF drugs, and genetic editing that uses data science-based bio information analysis, drug genomics, and screening technology which focuses on cancer vulnerable to cancer therapy, enabling the medical industry to avail effective drugs for incurable diseases with technology to improve human health and happiness.

Contact Information

Website
www.arontier.co
Formerly Known As
FURAME
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 15th Floor, 241, Gangnam-daero
  • Seocho-gu
  • Seoul
  • South Korea
Primary Industry
Discovery Tools (Healthcare)
Vertical(s)
Artificial Intelligence & Machine Learning, HealthTech, Life Sciences, Oncology
Corporate Office
  • 15th Floor, 241, Gangnam-daero
  • Seocho-gu
  • Seoul
  • South Korea

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arontier Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 02-Nov-2023 Completed Out of Business
1. Seed Round Completed Generating Revenue
To view Arontier’s complete valuation and funding history, request access »

Arontier Patents

  • 16

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 6

    Pending

  • Expiring in next 12 mo

Arontier Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025230352-A1 Pharmaceutical composition targeting cancer-associated fibroblasts Pending 03-May-2024
WO-2025080049-A1 Compound for inhibiting atx, preparation method therefor, and pharmaceutical composition for use in preventing or treating atx activity-related diseases containing same as active ingredient Inactive 13-Oct-2023
JP-2026527802-A A method for predicting protein-ligand interactions using a protein-ligand interaction prediction model. Pending 28-Jul-2023
WO-2025028700-A1 Method for predicting protein-ligand interaction using protein-ligand interaction prediction model Inactive 28-Jul-2023
WO-2023177171-A1 Retrosynthetic translation method using transformer and atomic environment, and device for performing same Inactive 17-Mar-2022 G16C20/70
To view Arontier’s complete patent history, request access »

Arontier Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Arontier FAQs

  • When was Arontier founded?

    Arontier was founded in 2017.

  • Where is Arontier headquartered?

    Arontier is headquartered in Seoul, South Korea.

  • What is the size of Arontier?

    Arontier has 12 total employees.

  • What industry is Arontier in?

    Arontier’s primary industry is Discovery Tools (Healthcare).

  • Is Arontier a private or public company?

    Arontier is a Private company.

  • What is Arontier’s current revenue?

    The current revenue for Arontier is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process